Status:

UNKNOWN

Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy

Lead Sponsor:

Assiut University

Conditions:

OctA .FFA Findings in DR

Eligibility:

All Genders

45-75 years

Brief Summary

Diabetic retinopathy (DR) is the leading cause of decreased vision in working age people. Patients with DR can develop macular edema and proliferative retinopathy which are major causes of visual impa...

Eligibility Criteria

Inclusion

  • All Pts with confirmed type 2 diabetes of at least 6 months. Best corrected visual Acuity of 6/60 or higher (using asnellen chart) in each eye

Exclusion

  • Dense media opacities interfere with image FFA as dense cataract . Previous TTT mainly retinal laser photocoagulation or intra vitreal injection. History of ocular disease as glaucoma and retinal vascular occlusion . Previous ocular surgery.

Key Trial Info

Start Date :

September 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2024

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05190965

Start Date

September 1 2022

End Date

February 1 2024

Last Update

January 13 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy | DecenTrialz